



ITW

PATENT
Attorney Docket No. 224491
Client Reference No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Rahman et al.

Application No. 10/717,378

Filed: November 19, 2003

Group Art Unit: 1654.

Examiner: Russel, Jeffrey

For: LIPOSOMAL FORMULATION OF
IRINOTECAN

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

- ☐ **within** any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

07/12/2005 SSITHIB1 00000006 121216 10717378

01 FC:1806

180.00 DA

- ☒ **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
- or*
- ☒ the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- ☐ **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

Copies of the References

- ☐ Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
- ☒ Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith.
- ☒ Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
- ☒ A copy of the foreign search report is enclosed herewith.
- ☐ The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining

Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLICATIONS		STATUS (check one)		
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.				
2.				
3.				

Statement under 37 CFR 1.97(e)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

- ☐ The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Fees

- ☐ No fee is owed by the applicant(s).
- ☒ Charge Deposit Account No. 12-1216 in the amount of **\$180.00** (37 CFR 1.17(p)).
(A duplicate copy of this communication is enclosed for that purpose.)


Authorization to Charge Additional Fees

- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

In re Appln. of Rahman et al.
Application No. 10/717,378

Instructions as to Overpayment

☒ Credit Account No. 12-1216.
☐ Refund




M. Daniel Hefner, Reg. No. 41,826
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: July 7, 2005

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 7, 2005



IDS (Revised 10/21/04)

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	10/717,378
Filing Date	November 19, 2003
First Named Inventor	Rahman et al.
Group Art Unit	1654
Examiner Name	Russel, Jeffrey
Attorney Docket Number	224491

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	AF	3,993,754		Rahman et al.	Nov. 23, 1976	
	AG	4,008,209		Fujino et al.	Feb. 15, 1977	
	AH	4,016,100		Suzuki et al.	Apr. 5, 1977	
	AI	4,115,544		Shell	Sep. 19, 1978	
	AJ	4,224,179		Schneider	Sep. 23, 1980	
	AK	4,229,360		Schneider et al.	Oct. 21, 1980	
	AL	4,235,871		Papahadjopoulos et al.	Nov. 25, 1980	
	AM	4,263,428		Apple et al.	Apr. 21, 1981	
	AN	4,311,712		Evans et al.	Jan. 19, 1982	
	AO	4,348,384		Horikoshi et al.	Sep. 7, 1982	
	AP	4,370,349		Evans et al.	Jan. 25, 1983	
	AQ	4,396,630		Riedl et al.	Aug. 2, 1983	
	AR	4,411,894		Schrank et al.	Oct. 25, 1983	
	AS	4,419,348		Rahman et al.	Dec. 6, 1983	
	AT	4,473,692		Miyasaka et al.	Sep. 25, 1984	
	AU	4,515,736		Deamer	May 7, 1985	
	AV	4,522,803		Lenk et al.	June 11, 1985	
	AW	4,545,880		Miyasaka et al.	Oct. 8, 1985	
	AX	4,610,868		Fountain et al.	Sep. 9, 1986	
	AY	4,721,612		Janoff et al.	Jan. 26, 1988	
	AZ	4,812,312		Lopez-Berestein et al.	Mar. 14, 1989	
	BA	4,857,319		Crowe et al.	Aug. 15, 1989	
	BB	4,952,408		Rahman	Aug. 28, 1990	
	BC	4,981,968		Wall et al.	Jan. 1, 1991	
	BD	5,023,087		Yau-Young	June 11, 1991	
	BE	5,077,057		Szoka, Jr.	Dec. 31, 1991	
	BF	5,112,837	A	Burrows et al.	May 12, 1992	
	BG	5,145,684	A	Liversidge et al.	Sep. 8, 1992	
	BH	5,162,532	A	Comins et al.	Nov. 10, 1992	
	BI	5,187,167	A	Hughes	Feb. 16, 1993	
	BJ	5,247,089	A	Comins et al.	Sep. 21, 1993	
	BK	5,352,789	A	Hinz	Oct. 4, 1994	
	BL	5,389,377	A	Chagnon et al.	Feb. 14, 1995	
	BM	5,391,745	A	Danishefsky et al.	Feb. 21, 1995	
	BN	5,415,867	A	Minchey et al.	May 16, 1995	
	BO	5,422,344	A	Priel et al.	June 6, 1995	
	BP	5,424,073	A	Rahman et al.	June 13, 1995	
	BQ	5,447,936	A	Hausheer et al.	Sep. 5, 1995	
	BR	5,468,859	A	Fortunak et al.	Nov. 21, 1995	

Examiner Signature

Date Considered

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	2	of	6		

	BS	5,475,108	A	Comins et al.	Dec. 12, 1995	
	BT	5,496,830	A	Shapiro et al.	Mar. 5, 1996	
	BU	5,504,102	A	Agharkar et al.	Apr. 2, 1996	
	BV	5,527,913	A	Hinz	June 18, 1996	
	BW	5,541,327	A	Danishefsky et al.	July 30, 1996	
	BX	5,552,154	A	Giovanella et al.	Sep. 3, 1996	
	BY	5,552,156	A	Burke	Sep. 3, 1996	
	BZ	5,560,923	A	Rahman et al.	Oct. 1, 1996	
	CA	5,608,066	A	Hinz	Mar. 4, 1997	
	CB	5,616,334	A	Janoff et al.	Apr. 1, 1997	
	CC	5,622,959	A	Priel et al.	Apr. 22, 1997	
	CD	5,648,090	A	Rahman et al.	July 15, 1997	
	CE	5,651,986	A	Brem et al.	July 29, 1997	
	CF	5,652,244	A	Giovanella et al.	Jul. 29, 1997	
	CG	5,665,710	A	Rahman et al.	Sep. 9, 1997	
	CH	5,674,873	A	Hausheer et al.	Oct. 7, 1997	
	CI	5,674,874	A	Hausheer et al.	Oct. 7, 1997	
	CJ	5,726,181	A	Hausheer et al.	Mar. 10, 1998	
	CK	5,736,156	A	Burke	Apr. 7, 1998	
	CL	5,759,767	A	Lakowicz et al.	June 2, 1998	
	CM	5,776,486	A	Castor et al.	July 7, 1998	
	CN	5,776,743	A	Frisch	July 7, 1998	
	CO	5,786,344	A	Ratain et al.	July 28, 1998	
	CP	5,837,282	A	Fenske et al.	Nov. 17, 1998	
	CQ	5,837,673	A	Tsujihara et al.	Nov. 17, 1998	
	CR	5,846,565	A	Brem et al.	Dec. 8, 1998	
	CS	5,859,022	A	Hausheer et al.	Jan. 12, 1999	
	CT	5,859,023	A	Hausheer et al.	Jan. 12, 1999	
	CU	5,880,133	A	Hausheer et al.	Mar. 9, 1999	
	CV	5,882,679	A	Needham	Mar. 16, 1999	
	CW	5,889,017	A	Giovanella et al.	Mar. 30, 1999	
	CX	5,900,419	A	Hausheer et al.	May 4, 1999	
	CY	5,916,596	A	Desai et al.	June 29, 1999	
	CZ	5,948,750	A	Garsky et al.	Sep. 7, 1999	
	DA	5,955,467	A	Hausheer et al.	Sep. 21, 1999	
	DB	5,958,937	A	Hausheer et al.	Sep. 28, 1999	
	DC	5,962,216	A	Trouet et al.	Oct. 5, 1999	
	DD	5,972,955	A	Duvvuri et al.	Oct. 26, 1999	
	DE	5,985,888	A	Wall et al.	Nov. 16, 1999	
	DF	5,998,426	A	Bedeschi et al.	Dec. 7, 1999	
	DG	6,015,901	A	Kawaguchi et al.	Jan. 18, 2000	
	DH	6,046,159	A	Hausheer et al.	Apr. 4, 2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	3	of	6		

	DI	6,056,973	A	Allen et al.	May 2, 2000	
	DJ	6,057,361	A	Hausheer et al.	May 2, 2000	
	DK	6,066,645	A	Hausheer et al.	May 23, 2000	
	DL	6,069,134	A	Roth et al.	May 30, 2000	
	DM	6,090,407	A	Knight et al.	July 18, 2000	
	DN	6,096,336	A	Cao et al.	Aug. 1, 2000	
	DO	6,146,659	A	Rahman	Nov. 14, 2000	
	DP	6,291,676	B1	Burke et al.	Sep. 18, 2001	
	DQ	6,355,268	B1	Slater et al.	Mar. 12, 2002	
	DR	6,461,637	B1	Rahman	Oct. 8, 2002	
	DS	6,548,071	B1	Cherian	Apr. 15, 2003	
	DT	6,740,335	B1	Moynihan et al.	May 25, 2004	
	DU	2002/0103141	A1	McKearn et al.	Aug. 1, 2002	
	DV	2001/0119990	A1	Madden et al.	Aug. 28, 2002	
	DW	2003/0059465	A1	Unger et al.	Mar. 27, 2003	
	DX	2003/0215492	A1	Ahmad et al.	Nov. 20, 2003	
	DY	2004/0009229	A1	Unger et al.	Jan. 15, 2004	
	DZ	11/061,044		Ahmad et al.		Feb. 18, 2005
	EA	60/247,306		Rahman et al.		Nov. 9, 2000
	EB	60/294,285		Rahman et al.		May 29, 2001
	EC	60/404,668		Rahman et al.		Aug. 20, 2002

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	ED	WO	83/03383	A1	The Liposome Co., Inc.	Oct. 13, 1983		
	EE	WO	86/01103	A1	The Liposome Co., Inc.	Feb. 27, 1986		
	EF	WO	93/18751	A1	Georgetown University	Sep. 30, 1993		
	EG	WO	95/08386	A1	Smithkline Beecham Corp.	April 6, 1995		
	EH	WO	96/11669	A1	Pharmacia, Inc.	April 25, 1996		
	EI	WO	98/17256	A1	Kirpotin	April 30, 1998		
	EJ	WO	99/13816	A2	Nexstar Pharmaceuticals, Inc.	March 25, 1999		
	EK	WO	99/51202	A2	Sequus Pharmaceuticals, Inc.	Oct. 14, 1999		
	EL	WO	00/23052	A1	ALZA Corp.	April 27, 2000		
	EM	WO	02/00168	A2	Supergen, Inc.	Jan. 3, 2002		
	EN	WO	02/058622	A2	Neopharm, Inc.	Aug. 1, 2003		
	EO	WO	03/030864	A1	Neopharm, Inc.	Apr. 17, 2003		
	EP	WO	03/103596	A2	Imarx Therapeutics, Inc.	Dec. 18, 2003		
	EQ	WO	04/017940	A3	Neopharm, Inc.	Mar. 4, 2004		
	ER	WO	04/035032	A2	Neopharm, Inc.	April 29, 2004		
OTHER - NON PATENT LITERATURE DOCUMENTS								
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item					Translation	

Examiner Signature	Date Considered
--------------------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	4	of	6		

Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**
	ES	AKHTAR et al., <i>Journal of Controlled Release</i> , 22: 47-56 (1992)		
	ET	ALLEN et al., <i>Biochimica et Biophysica Acta</i> , 981(1): 27-35 (May 19, 1989)		
	EU	ALLEN et al., <i>Cancer Research</i> , 52: 2431-2439 (May 1, 1992)		
	EV	BLUME et al., <i>Biochimica et Biophysica Acta</i> , 1029(1): 91-97 (Nov. 2 1990)		
	EW	BURKE et al., <i>Journal of the American Chemical Society</i> , 114(21): 8318-8319 (Oct. 7, 1992)		
	EX	BURKE et al., <i>Biochemistry</i> , 32(20): 5352-5364 (May 25, 1993)		
	EY	BURRIS et al., <i>Journal of the National Cancer Institute</i> , 84(23), No. 23: 1816-1820 (Dec. 2, 1992)		
	EZ	CAVALETTI et al., <i>Toxicology Letters</i> , 118: 103-107 (2000)		
	FA	Cecil Textbook of Medicine, 15 th Edition, Vol. 1: 396-399, 475-479 and 817-821 (1997)		
	FB	CHAKRABARTI et al., <i>Biochimica et Biophysica Acta</i> , 1108(2): 233-239 (1992)		
	FC	CLEMENTS et al., <i>Cancer Chemother Pharmacol</i> , 44: 411-416 (1999)		
	FD	CROMMELIN et al., <i>Pharmaceutical Research</i> , 4: 159-163 (July 1984)		
	FE	CROWE et al., <i>Archives of Biochemistry And Biophysics</i> , 220(2): 477-484 (Feb. 1983)		
	FF	CROWE et al., <i>Archives of Biochemistry And Biophysics</i> , 232(1): 400-407 (Jul. 1984)		
	FG	CROWE et al., <i>Biochimica et Biophysica</i> , 769: 151-159 (1984)		
	FH	CROWE et al., <i>Biochimica et Biophysica</i> , 769: 141-150 (1984)		
	FI	CROWE et al., <i>Archives Biochemistry And Biophysics</i> , 242(1): 240-247 (Oct. 1985)		
	FJ	DAOUD et al., <i>Cancer Research</i> , 49: 2661-2667 (1989)		
	FK	DEAMER et al., <i>Liposomes</i> , (Ostro, eds), 27-51 (Marcel Dekker, Inc., New York, NY, 1983)		
	FL	DRUCKMANN et al., <i>Biochimica et Biophysica Acta</i> , 980(2): 381-384 (1989)		
	FM	EMERSON et al., <i>Cancer Research</i> , 55: 603-609 (1995)		
	FN	EMERSON et al., <i>Pharmaceutical Science & Technology Today</i> , 3(6): 205-209 (June 2000)		
	FO	ERICKSON-MILLER et al., <i>Cancer Chemother Pharmacol</i> , 39: 467-472 (1997)		
	FP	FAN et al., <i>Cancer Research</i> , 50: 3619-3626 (Jun. 15, 1990)		
	FQ	FORSSEN et al., <i>Biochemical And Biophysical Research Communications</i> , 91(4): 1295-1301 (Dec. 28, 1979)		
	FR	FORSSEN et al., <i>Cancer Research</i> , 43: 546-550 (1983)		
	FS	FORSSEN et al., <i>Cancer Research</i> , 52: 3255-3261 (1992)		
	FT	FRY et al., <i>Analytical Biochemistry</i> , 90: 809-815 (1978)		
	FU	GABIZON et al., <i>Proc. Natl. Acad. Sci. USA</i> , 85: 6949-6953 (Sep. 1988)		
	FV	GABIZON et al., <i>Cancer Research</i> , 50: 6371-6378 (Oct. 1, 1990)		
	FW	GARCIA-CARBONERO et al., <i>Clinical Cancer Research</i> , 8: 641-661 (Mar. 2002)		
	FX	GIOVANELLA et al., <i>Science</i> , 246(4933): 1046-1048 (Nov. 24, 1989)		
	FY	GIOVANELLA et al., <i>Cancer Research</i> , 51: 3052-3055 (Jun. 1, 1991)		
	FZ	GOKHALE et al., <i>British Journal of Cancer</i> , 74: 43-48 (1996)		
	GA	GREEN CROSS CORPORATION, <i>Chemical Abstracts</i> , 97:11851g: (1982)		
	GB	GREGORIADIS et al., <i>The New England Journal of Medicine</i> , 295(12): 704-710 (1976)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	5	of	6		

	GC	GROCHOW et al., <i>Drug Metabolism and Disposition</i> , 20(5): 706-713 (1992)		
	GD	GUICHARD et al., <i>Clinical Cancer Research</i> , 4: 3089-3094 (Dec. 1998)		
	GE	HARDMAN et al., <i>Anticancer Research</i> , 19: 2269-2274 (1999)		
	GF	HARDMAN et al., <i>British Journal of Cancer</i> , 81(3): 440-8 (Oct. 1999)		
	GG	HILLERY, <i>Advanced Drug Delivery Reviews</i> , 24(2 & 3): 345-363 (1997)		
	GH	HONG et al., <i>J. Med. Chem.</i> , Computer Search Listing Abstract (May 1990)		
	GI	HONG et al., <i>Cancer Research</i> , Computer Search Listing Abstract (Jul. 15, 1990)		
	GJ	HSIANG et al., <i>Cancer Research</i> , 48: 1722-1726 (Apr. 1, 1988)		
	GK	HUANG et al., <i>Cancer Research</i> , 52: 5135-5143 (Oct. 1, 1992)		
	GL	INNOCENTI et al., <i>Drug Metabolism & Dispositions</i> , 29(4): 596-600 (2001)		
	GM	JANOFF et al., <i>Journal of Liposome Research</i> , 3(3): 451-471 (1993)		
	GN	JANSEN et al., <i>International Journal of Cancer</i> , 70(3): 335-340 (Jan. 27, 1997)		
	GO	JETT et al., <i>Methods in Enzymology</i> , 141: 459-466 (1983)		
	GP	KAWATO et al., <i>Cancer Research</i> , 51(16): 4187-91 (Aug. 15, 1991)		
	GQ	KAWATO et al., <i>Cancer Chemotherapy and Pharmacology</i> , 28(3): 192-198 (1991)		
	GR	KILLION et al., <i>Journal of the National Cancer Institute</i> , 81(18): 1387-1392 (Sep. 6, 1989)		
	GS	KNOTTING et al., <i>Cancer-Chemother-Pharmacol.</i> , Computer Search Listing Abstract (1992)		
	GT	LASIC, <i>American Scientist</i> , 80(1): 20-31 (Jan.-Feb.1992)		
	GU	LASIC, <i>Nature</i> , 355(6357): 272-280 (Jan. 16, 1992)		
	GV	LAVELLE et al., <i>Seminars in Oncology</i> 23(1) Suppl.3: 11-20 (Feb. 1996)		
	GW	LUNDBERG, <i>Anti-Cancer Drug Design</i> , 13: 453-461 (1998)		
	GX	MACHIDA et al., <i>Journal of Controlled Release</i> , 66: 159-175 (2000)		
	GY	MACHY et al., <i>Biochimica et Biophysica Acta.</i> , 730: 313-320 (1983)		
	GZ	MADDEN et al., <i>Biochimica et Biophysica Acta.</i> , 817: 67-74 (1985)		
	HA	MADDEN et al., <i>Chemistry and Physics of Lipids</i> , 53: 37-46 (1990)		
	HB	MADDEN et al., <i>Proc. Of ASCO</i> , 17:abstract #754: (1998)		
	HC	MARGALIT et al., <i>Journal of Controlled Release</i> , 17(3): 285-296 (1991)		
	HD	MATHIJSEN et al., <i>Clinical Cancer Research</i> , 7: 2182-2194 (Aug. 2001)		
	HE	MAYER et al., <i>Cancer Research</i> , 49: 5922-5930 (1989)		
	HF	MAYER et al., <i>Biochimica et Biophysica Acta.</i> , 1025: 143-151 (1990)		
	HG	MCCABE et al., <i>Cancer Investigation</i> , 12(3): 308-313 (1994)		
	HH	MONKS et al., <i>Journal of the National Cancer Institute</i> , (83(11): 757-766 (Jun. 5, 1991)		
	HI	OKUNO et al., <i>Cancer Research</i> , 60: 2988-2995 (Jun. 1, 2000)		
	HJ	O'LEARY et al., <i>Clinical Cancer Research</i> , 5: 181-187 (Jan. 1999)		
	HK	OLITZKI, <i>In vivo Procedures</i> , <i>Bibliotheca Microbiologica</i> , 9: 196-203 (1970)		
	HL	ORMROD et al., <i>ADIS Drug Evaluation</i> , 58(3): 534-551 (1999)		
	HM	PAGANO, <i>Annual Review of Biophysics and Bioengineering</i> , 7: 435-468 (1978)		
	HN	PALMISANO et al., <i>Anal-Chem.</i> , Computer Listing Search Abstract, (May 1, 1989)		
	HO	PANTAZIS et al., <i>Cancer Research</i> , 52: 3980-3987 (Jul. 15, 1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/717,378
				Filing Date	November 19, 2003
				First Named Inventor	Rahman et al.
				Group Art Unit	1654
				Examiner Name	Russel, Jeffrey
				Attorney Docket Number	224491
Sheet	6	of	6		

	HP	PAPAHADJOPOULOS et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88: 11460-11464 (Dec. 1991)		
	HQ	PARTEARROYO et al., <i>FEBS Letters</i> , 302(2): 138-140 (May 1992)		
	HR	PEJAVER et al., <i>Drug Development and Industrial Pharmacy</i> , 13(15): 2633-2649 (1987)		
	HS	PEREZ-SOLAR, <i>Cancer Treatment Reviews</i> , 16(2): 67-82 (Jun. 1989)		
	HT	PEREZ-SOLER et al., <i>Cancer Research</i> , 50: 4254-4259 (Jul. 15, 1990)		
	HU	PINNADUWAGE et al., <i>Biochemistry</i> , 31(11): 2850-2855 (Mar. 24, 1992)		
	HV	PIZZOLATO et al., <i>Lancet</i> , 361: 2235-2242 (Jun. 28, 2003)		
	HW	POTMESIL et al., <i>DNA Topoisomerases Cancer, Chemical Abstract 117(103,369):</i> (1991)		
	HX	RACKER, <i>J. Membrane Biol.</i> , 10: 221-235 (1972)		
	HY	RAHMAN et al., <i>Cancer Research</i> , 45: 796-803 (Feb. 1985)		
	HZ	RAHMAN et al., <i>J. of the Nat. Cancer Institute</i> , 81(23): 1794-1800 (Dec. 6, 1989)		
	IA	RATAIN et al., <i>Journal of Clinical Oncology</i> , 20(1): 7-8 (Jan. 1, 2002)		
	IB	RIEGER, <i>Pharmaceutical Dosage Forms Disperse System</i> , 1(8): 334-338 (1988)		
	IC	SENIOR et al., <i>Biochimica et Biophysica Acta</i> , 1070: 173-179 (1991)		
	ID	SHELLY et al., <i>Proc. Natl. Acad. Sci. USA</i> , 89: 9039-9043, (Oct. 1992)		
	IE	SHULKIN et al., <i>J. Microencapsulation</i> , 1(1): 73-80 (1984)		
	IF	STORM et al., <i>Cancer Research</i> , 47: 3366-3372 (Jul. 1, 1987)		
	IG	SUGARMAN et al., <i>1-Pharmacology, Chemical Abstract No. 124:332078g, 124(25): 94</i> (1996)		
	IH	SUPERSAXO et al., <i>Pharmaceutical Research</i> , 8(10): 1286-1291 (Oct. 1991)		
	II	SZOKA et al., <i>Proc. Natl. Acad. Sci. USA</i> , 75(9): 4194-4198 (Sep. 1978)		
	IJ	SZOKA, <i>Ann. Rev. Biophys. Bioeng.</i> , 9: 467-508 (1980)		
	IK	TARDI et al., <i>Cancer Research</i> , 60: 3389-3393 (Jul 1, 2000)		
	IL	THIES et al., <i>Analytical Biochemistry</i> , 188: 65-71 (1990)		
	IM	THOMPSON et al., <i>Biochimica et Biophysica Acta</i> , 1400: 301-319 (1998)		
	IN	TOPCHIEVA et al., <i>Biomed-Sci., Computer Listing Search Abstract</i> , (1991)		
	IO	TSYGANENKO et al., <i>Antibiotiki</i> , 28(8): 577-581 (1983)		X ⁺
	IP	USOV et al., <i>Bioorg-Khim</i> , Computer Listing Search Abstracts, (1991)		
	IQ	VION-DURY et al., <i>J. Pharm. And Exp. Therapeutics</i> , 250(3): 1113-1119 (1989)		
	IR	WADKINS et al., <i>Cancer Research</i> , 59(14): 3424-8 (Jul 15, 1999)		
	IS	WALL et al., <i>J. of the American Chem. Soc.</i> , 88(16): 3888-3890 (1966)		
	IT	WEINSTEIN, <i>Liposomes</i> , (Ostro eds), 277-338 (Marcel Dekker, Inc., New York, NY, 1983)		
	IU	WILLIAMS et al., <i>J. Controlled Release</i> , 91: 167-172 (2003)		
	IV	WOODLE et al., <i>Methods in Enzymology</i> , 171: 193-217 (1989)		
	IW	WU et al., <i>Chemical Abstracts</i> , 99:163963z: (1983)		
	IX	YOKOYAMA et al., <i>Cancer-Res.</i> , Computer Listing Search Abstract, (1991)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).